On Monday, Xeris Biopharma Holdings Inc (NASDAQ: XERS) was -3.45% drop from the session before settling in for the closing price of $2.61. A 52-week range for XERS has been $1.46 – $3.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 195.35% over the past five years. When this article was written, the company’s average yearly earnings per share was at 19.74%. With a float of $137.79 million, this company’s outstanding shares have now reached $138.13 million.
Let’s look at the performance matrix of the company that is accounted for 377 employees.
Xeris Biopharma Holdings Inc (XERS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Xeris Biopharma Holdings Inc stocks. The insider ownership of Xeris Biopharma Holdings Inc is 7.06%, while institutional ownership is 38.61%. The most recent insider transaction that took place on May 10 ’24, was worth 10,314. In this transaction Director of this company bought 5,400 shares at a rate of $1.91, taking the stock ownership to the 16,400 shares. Before that another transaction happened on Mar 14 ’24, when Company’s Director bought 4,500 for $2.16, making the entire transaction worth $9,720. This insider now owns 11,000 shares in total.
Xeris Biopharma Holdings Inc (XERS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 19.74% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
You can see what Xeris Biopharma Holdings Inc (XERS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.46, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.17 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Xeris Biopharma Holdings Inc (NASDAQ: XERS) saw its 5-day average volume 1.26 million, a negative change from its year-to-date volume of 1.77 million. As of the previous 9 days, the stock’s Stochastic %D was 75.52%. Additionally, its Average True Range was 0.13.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 61.48%, which indicates a significant decrease from 71.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.47% in the past 14 days, which was lower than the 63.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.24, while its 200-day Moving Average is $2.18. Nevertheless, the first resistance level for the watch stands at $2.63 in the near term. At $2.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.82. If the price goes on to break the first support level at $2.44, it is likely to go to the next support level at $2.37. The third support level lies at $2.25 if the price breaches the second support level.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
There are 148,256K outstanding shares of the company, which has a market capitalization of 373.62 million. As of now, sales total 163,910 K while income totals -62,260 K. Its latest quarter income was 40,640 K while its last quarter net income were -18,980 K.
